Ipilimumab/nivolumab/pembrolizumabImmune related adverse events : 4 case reports

被引：0
作者：
机构：
来源：
Reactions Weekly | 2020年 / 1791卷 / 1期
关键词：
D O I：
10.1007/s40278-020-74996-z
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：151 / 151
相关论文
共 50 条
[41]   Iobitridol/ipilimumab/pembrolizumabImmune thrombocytopenia: 2 case reports [J].
Reactions Weekly, 2016, 1594 (1) :111-111
[42]   Ipilimumab/nivolumab/pembrolizumabThyroiditis and endocrine disorders: 4 case reports [J].
Reactions Weekly, 2018, 1713 (1) :205-205
[43]   Ipilimumab/nivolumab/pembrolizumabLichenoid drug reaction: 4 case reports [J].
Reactions Weekly, 2018, 1706 (1) :282-282
[44]   PembrolizumabImmune-related dermatologic adverse events: 10 case report [J].
Reactions Weekly, 2022, 1889 (1) :261-261
[45]   PembrolizumabImmune-related adverse events and skin rash: case report [J].
Reactions Weekly, 2021, 1839 (1) :252-252
[46]   Ipilimumab/nivolumabImmune related adverse events: case report [J].
Reactions Weekly, 2019, 1749 (1) :226-226
[47]   Ipilimumab/nivolumab/pembrolizumabEncephalopathy, colitis and acquired resistance to pembrolizumab and ipilimumab: 4 case reports [J].
Reactions Weekly, 2019, 1768 (1) :199-199
[48]   PembrolizumabImmune related adverse events in the form of skin rash and pneumonitis: case report [J].
Reactions Weekly, 2022, 1927 (1) :443-443
[49]   Adverse events induced by nivolumab and ipilimumab combination regimens [J].
Somekawa, Kohei ;
Horita, Nobuyuki ;
Kaneko, Ayami ;
Tagami, Yoichi ;
Fukuda, Nobuhiko ;
Matsumoto, Hiromi ;
Namkoong, Ho ;
Fujiwara, Yu ;
Minegishi, Kaoru ;
Fukumoto, Takeshi ;
Watanabe, Keisuke ;
Hara, Yu ;
Kobayashi, Nobuaki ;
Kaneko, Takeshi .
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
[50]   Nivolumab/pembrolizumabImmune-mediated colitis: 2 case reports [J].
Reactions Weekly, 2025, 2040 (1) :758-758
12345